SAN DIEGO, Nov. 10, 2017 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that it will
present nonclinical data at the 32nd Annual Meeting of
the Society for Immunotherapy of Cancer (SITC) which demonstrate
the potential for PEGPH20, Halozyme's pegylated recombinant human
hyaluronidase, to increase the infiltration of immune cells into
the tumor microenvironment and enhance the efficacy of
immuno-oncology drugs in an HA-accumulating murine colon tumor
model.
The study shows that degradation of hyaluronan (HA) in a tumor
by PEGPH20 can facilitate an anti-tumor immune response induced by
checkpoint blockade by promoting effector cell infiltration and
skewing the immune microenvironment toward a more anti-tumor
composition. The data support Halozyme's ongoing clinical
evaluation of PEGPH20 in combination with checkpoint
inhibitors.
The poster, entitled "Degradation of hyaluronan by PEGPH20
promotes anti-tumor immunity and enhances the effect of checkpoint
blockade in an HA-accumulating mouse syngeneic tumor model," will
be presented as part of a series of posters focusing on the tumor
microenvironment from 12:30 p.m. to 2 p.m.
EST on Saturday, November
11.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program,
investigational drug PEGPH20, applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for metastatic
pancreatic cancer, non-small cell lung cancer, gastric cancer,
metastatic breast cancer and has potential across additional
cancers in combination with different types of cancer therapies. In
addition to its proprietary product portfolio, Halozyme has
established value-driving partnerships with leading pharmaceutical
companies including Roche, Baxalta, Pfizer, Janssen, AbbVie,
Lilly and Bristol-Myers Squibb for
its ENHANZE® drug delivery technology. Halozyme is headquartered in
San Diego. For more information
visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements (including, without
limitation, statements concerning the possible activity, benefits
and attributes of PEGPH20, the possible method of action of
PEGPH20, its potential application to improve cancer therapies and
statements concerning future actions relating to the development of
PEGPH20) that involve risk and uncertainties that could cause
actual results to differ materially from those in the
forward-looking statements. The forward-looking statements are
typically, but not always, identified through use of the words
"believe," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar
meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including unexpected expenditures and costs,
unexpected results or delays in development and regulatory review,
regulatory approval requirements, unexpected adverse events and
competitive conditions. These and other factors that may result in
differences are discussed in greater detail in the Company's most
recent Annual and Quarterly Reports filed with the Securities and
Exchange Commission.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-present-nonclinical-data-at-sitc-2017-supporting-combination-of-pegph20-with-checkpoint-inhibitors-300553695.html
SOURCE Halozyme Therapeutics, Inc.